The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 06, 2024

Filed:

Dec. 13, 2018
Applicant:

North Carolina State University, Raleigh, NC (US);

Inventors:

Zhen Gu, Los Angeles, CA (US);

Chao Wang, Raleigh, NC (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61P 35/00 (2006.01); A61K 9/00 (2006.01); A61K 31/7068 (2006.01); A61K 38/17 (2006.01); A61K 39/395 (2006.01);
U.S. Cl.
CPC ...
A61K 39/3955 (2013.01); A61K 9/0024 (2013.01); A61K 31/7068 (2013.01); A61K 38/1709 (2013.01); A61P 35/00 (2018.01);
Abstract

Disclosed herein are methods of treating/inhibiting/reducing a non-immunogenic cancer in a subject or inducing blockade inhibitor susceptibility (such as, for example, PD-1/PDLI, CTLA-4/B7-1/2, and/or CD47/SIRPa inhibitor susceptibility) in a tumor in a subject with a cancer, said methods comprising administering to the subject a hydrogel matrix comprising a chemotherapeutic agent (including, but not limited to gemcitabine) and a blockade inhibitor (including, but not limited to a PD-1/PD-LI blockade inhibitor, such as, for example nivolumab, pembrolizumab, pidilizumab, atezolizumab, avelumab, durvalumab, and BMS-936559; a CTLA-4/B7-1/2 inhibitor such as, for example, Ipilimumab; and/or a CD47/SIRPa inhibitor such as, for example Hu5F9-G4, CVI, B6H12, 2D3, CC-90002, and TTI-621).


Find Patent Forward Citations

Loading…